(PD Test)Heart Failure Society of America (HFSA) 2022 Annual Scientific Meeting

(PD Test)Heart Failure Society of America (HFSA) 2022 Annual Scientific Meeting

Maryland, US 11 October 2024 - 31 October 2024
Lower all-cause death, fewer HF events with empagliflozin in acute HF
Lower all-cause death, fewer HF events with empagliflozin in acute HF
11 Oct 2024 byRoshini Claire Anthony

Patients hospitalized with acute heart failure (HF) have a reduced risk of subsequent HF events or all-cause mortality if treated with once-daily empagliflozin while in hospital, according to results of the EMPULSE trial presented at HFSA 2022.

Lower all-cause death, fewer HF events with empagliflozin in acute HF
11 Oct 2024